MaxCyte Appoints New Chief Medical Officer
Ticker: MXCT · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1287098
Sentiment: neutral
Topics: executive-appointment, personnel
Related Tickers: MXCT
TL;DR
MaxCyte just hired a new CMO, Dr. Patel, from Verastem. Big move for their clinical strategy.
AI Summary
MaxCyte, Inc. announced on October 14, 2024, the appointment of Dr. Aris D. T. K. K. Patel as Chief Medical Officer. Dr. Patel brings extensive experience in clinical development and medical affairs, previously serving as Senior Vice President and Chief Medical Officer at Verastem Oncology. This appointment is part of MaxCyte's ongoing efforts to strengthen its leadership team as it advances its therapeutic programs.
Why It Matters
The appointment of a new Chief Medical Officer signals MaxCyte's commitment to advancing its clinical pipeline and potentially accelerating the development of its therapeutic candidates.
Risk Assessment
Risk Level: medium — The appointment of a new executive can introduce uncertainty regarding strategic direction and execution, although it also signals a focus on growth.
Key Players & Entities
- MaxCyte, Inc. (company) — Registrant
- Dr. Aris D. T. K. K. Patel (person) — Newly appointed Chief Medical Officer
- Verastem Oncology (company) — Previous employer of Dr. Patel
- October 14, 2024 (date) — Date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer at MaxCyte, Inc.?
Dr. Aris D. T. K. K. Patel has been appointed as the new Chief Medical Officer.
When was Dr. Patel's appointment effective?
The appointment was effective as of October 14, 2024.
What was Dr. Patel's previous role?
Dr. Patel previously served as Senior Vice President and Chief Medical Officer at Verastem Oncology.
What is MaxCyte, Inc.'s primary business?
MaxCyte, Inc. is involved in commercial physical & biological research, with a focus on therapeutic programs.
What is the filing date of this 8-K report?
This 8-K report was filed on October 15, 2024.
Filing Stats: 804 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2024-10-15 16:40:06
Key Financial Figures
- $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
Filing Documents
- mxct-20241014x8k.htm (8-K) — 42KB
- mxct-20241014xex99d1.htm (EX-99.1) — 27KB
- mxct-20241014xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-013318.txt ( ) — 204KB
- mxct-20241014.xsd (EX-101.SCH) — 3KB
- mxct-20241014_lab.xml (EX-101.LAB) — 16KB
- mxct-20241014_pre.xml (EX-101.PRE) — 10KB
- mxct-20241014x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 15, 2024, the Company issued a press release announcing Ms. Collins' appointment. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated as of October 15, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: October 15, 2024 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer